Header

In the News

03 April 2011 | HedgeWeek

SRI Initiative

Bernheim Dreyfus launches charity initiative

Alternative investment firm Bernheim, Dreyfus & Co has partnered with the French Foundation for Disabled (APSH 34), a charitable association which helps the psychiatrically disabled through their rehabilitation and the process of reintegration into society.

17 Feb 2011 | Bloomberg

Lionel Melka comments on the Sanofi-Genzyme deal

Sanofi Viehbacher wins Genzyme growth with hard line offer

“Genzyme is a huge achievement for Chris Viehbacher,” said Lionel Melka, co-manager of Paris-based Bernheim, Dreyfus & Co.’s Diva Synergy Fund. “It turns the company from being a value stock into a growth stock.”

16 Feb 2011 | Bloomberg

Lionel Melka comments on the Sanofi-Genzyme deal

Sanofi to buy Genzyme for sweetened $20.1 billion after nine-month pursuit

The difference between Genzyme’s share price and Sanofi’s offer reflects the worth investors are putting on the contingent value right, said Lionel Melka, co-manager of Paris-based Bernheim, Dreyfus & Co.’s Diva Synergy Fund, which focuses on acquisition targets.

16 Feb 2011 | Bloomberg

Lionel Melka on the Sanofi - Genzyme deal

Genzyme Holders Take the Money and Run on Drug CVR

The difference between Genzyme’s share price and Sanofi’s offer reflects the worth investors are putting on the contingent value right, said Lionel Melka, co-manager of Paris-based Bernheim, Dreyfus & Co.’s Diva Synergy Fund, which focuses on acquisition targets.

10 11 12 13 14 15 16 17 18 |  19 |  20 21 22 23 24 25 26 27 28 29 30 31 32 33 34